Studies investigating lung cancer have shown that IGF2BP3 is immunogenic as assessed by the presence of an antibody against recombinant IGF2BP3 in lung pleural effusions (Wang et al., 2003), and immunogenic peptides derived from IGF2BP3 induce tumor-reactive and human leukocyte antigen (HLA)-A2 (A∗02:01)-restricted cytotoxic T lymphocytes (CTL) (Tomita et al., 2011). The gene discussed is IGF2BP3; the disease is lung cancer.